ExoCoBio Inc. announced that it has received $9.3 million in its Series C and Pre-IPO funding on August 25, 2020. The transaction included participation from existing investors K2 Investment Partners LLC, SBI Investment Korea Co., Ltd. (KOSDAQ:A019550), Dt&Investment Co.,Ltd., and new investors KNOTUS Co.,Ltd (KOSDAQ:A278650), ReeHu Investment, G.N.TECH Venture Capital Co., Ltd., and Focus Asset Management Co., Ltd. The company has raised $56.3 million in funding till date.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,290 KRW | +4.09% | -34.10% | -25.89% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.89% | 141M | |
-30.89% | 9.3B | |
-8.50% | 3.1B | |
+27.12% | 2.87B | |
-14.31% | 2.17B | |
-19.19% | 1.75B | |
+70.84% | 1.5B | |
+30.00% | 807M | |
-1.97% | 759M | |
-26.53% | 532M |
- Stock Market
- Equities
- A278650 Stock
- News HLB bioStep Co.,Ltd.
- ExoCoBio Inc. announced that it has received $9.3 million in funding from a group of investors